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The crystal structure of spiro[2.2"]acenaphthene-1"-
onespiro[3.3']-5'-(2-bromophenylmethylidene)-1'-
me t h y lp ip e r i d in -4 ' -o n e -4 - ( 2 -b r o mo p he n y l )
octahydroindolizine (Ia) and spiro[2.2"]acenaphthene-
1"-onespiro[3.3']-5'-(4-bromophenylmethylidene)-1'-
me t h y lp ip e r i d in -4 ' -o n e -4 - ( 4 -b r o mo p he n y l )
octahydroindolizine (Ib) were elucidated  by single 
crystal X ray diffraction. Compound (Ia), 
C37H32Br2N2O2, crystallizes in the Orthorombic  sys-
tem, space group  P212121 with a = 9.6989(5) Å, b = 
16.3615(9) Å, c = 19.8997(11) Å and Z = 4. Com-
pound (Ib), having the same molecular formula, crys-
tallizes in the monoclinic system, space group P 21/n 
with a = 8.3169(5) Å, b = 16.9397(9) Å, c= 22.2466
(13) Å, β = 96.943(3)° and Z = 4. The central 
piperidine ring adopts twisted conformation, the 
piperidine of octahydroindolizine ring is in half chair 
conformation and the pyrrole ring is in twisted enve-
lope conformation in both the compounds (Ia) and 
(Ib). Details of the preparation, NMR and crystal 
structure determination and intra- and inter- molecular 
interactions of the compounds are given. 
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Spectral analysis and crystal structure of  two substituted spiro acenaphthene 
structures 
Introduction 
 
Tuberculosis (TB) is an infectious disease caused by 
the bacterium Mycobacterium tuberculosis (MTB), 
which usually attacks the lungs but may also affect 
other parts of the body. This has been one of the most 
prevalent diseases responsible for the death of approxi-
mately one billion people during the last two centuries. 
TB remains a severe public health problem in India, 
accounting for nearly one-third of the global burden, 
and it has been estimated that 3.5 million people are 
infected with TB in that country alone (Granich et al. 
2003) In the past years, only a few drugs have been 
approved by the Food and Drug Administration (FDA) 
to treat TB, which reflects the inherent difficulties in 
the discovery and clinical testing of new agents 
(O’Brien et al. 2001). Hence, the discovery of fast-
acting new drugs to effectively combat TB is  impera-
tive.  
 In general, spiro compounds (Chande et al. 
2005, Dandia et al. 2003) and nitrogen heterocycles 
(Sriram et al. 2006, Biava et al. 2006, Shaharyar et al. 
2006) display good antimycobacterial activities. Re-
cently, we reported an atom economic synthesis and 
evaluation of antimycobacterial activities of spiro 
pyrido-pyrrolizines and pyrrolidines, (Compounds 1–
4) (Ranjith Kumar et al. 2008) which inhibited in vitro 
MTB and multi-drug resistant Mycobacterium tubercu-
losis (MDR-TB). In the course of screening to discover 
new compounds that could be useful for the treatment 
of TB, we herein report the synthesis, NMR spectra 
and single crystal X-ray studies of two novel spiro 
compounds, (Ia) and (Ib). The chemical diagrams of 
the compounds (Ia) and (Ib) are shown in Figure 1. 
 In addition, it is also pertinent to note that the 
synthesis of biologically active indolizine derivatives 
continues to attract the attention of organic chemists, 
because of their wide spectrum of biological activity. 
Indolizine derivatives have been found to possess a 
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Figure 1. Chemical diagram of the molecule (Ia) (left) and 
(Ib) (right). 
variety of biological activities such as anti-
inflammatory (Malonne et al. 1998), antiviral (Medda 
et al. 2003), aromatase inhibitory (Sonnet et al. 2000) 
as well as analgestic and antitumor (Pearson et al. 
2001) ones. A brief survey of the Cambridge Structural 
Database (Version 5.33; Allen 2002) revealed a scar-
city of precise crystallographic data on octahydroindol-
izine ring systems; hence, these structures are pre-
sumed to be very interesting and rarely studied moie-
ties. 
 
Experimental 
 
Preparation of compound (Ia)  
A mixture of 1-methyl-3,5-bis[(E)-2-bromo phenyl-
methylidene]tetrahydro-4(1H)-pyridinone (1 mmol), 
acenaphthenequinone  (1 mmol) and piperidine-2-
carboxylic acid (1 mmol) was dissolved in isopropyl 
alcohol (15 mL) and heated to reflux for 60 min. After 
completion of the reaction as evident from TLC, the 
mixture was poured into water (50 mL), the precipi-
tated solid was filtered and washed with water (100 
mL) to obtain pure yellow solid having a melting point 
of 226°C  (Yield : 95%). 
 
Preparation of compound (Ib)  
A mixture of 1-methyl-3,5-bis[(E)-4-bromo phenyl-
methylidene]tetrahydro-4(1H)-pyridinone (1 mmol), 
acenaphthenequinone  (1 mmol) and piperidine-2-
carboxylic acid (1 mmol) was dissolved in isopropyl 
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Figure 2. 1H and 13C NMR chemical shifts of (Ia) (left) and (Ib) (right). 
Empirical formula C37H32Br2N2O2 C37H32Br2N2O2 
Formula weight 696.47 696.47 
Temperature 293(2) K 293(2) K 
Wavelength 0.71073 Å 0.71073 Å 
Crystal system, space group P212121, orthorhombic P 21/n,  monoclinic 
Unit cell dimensions 
a = 9.6989(5)Å 
b=16.3615(9)Å 
c = 19.8997(11)Å 
a = 8.3169(5)Å, 
b =16.9397(9) Å, 
c = 16.9397(9)Å,β=96.943(3)° 
Volume  3157.85 (3) Å3 3111.2(3) A3 
Z, Calculated density 4,  1.46mg/m3 4,  1.487 mg/m3 
Absorption coefficient 2.603 mm-1 2.642  mm-1 
F(000) 1416 1416 
Crystal size 0.19x0.16x0.14mm3 0.17x0.14x0.11mm3 
Theta range for data collection 1.6 to 28.3deg 1.52 to 28.44 deg 
Limiting indices 
-12<=h<=12,-11,=k<=20 
-25<=l<=26 
-10<=h<11,-22<=k<21, 
-29<=l<=29 
Reflections collected / unique 17252 / 7629 [R(int) = 0.0288] 29716 / 7760[Rint = 0.0649] 
Completeness to theta 98.3 % 98.9% 
Absorption correction ω –scan ω –scan 
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2 
Data / restraints / parameters 7629 / 0 / 389 7760/ 0/ 389 
Goodness-of-fit on F2 1.006 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0394, wR2 = 0.0701 R1 = 0.0510, wR2 = 0.1034 
R indices (all data) R1 = 0.0803, wR2 = 0.0778 R1 = 0.1131, wR2 = 0.1220 
Largest diff. peak and hole 0.517 and -0.549 eA-3 0.406  and  -0.606  eÅ -3 
Table 1. The crystal data, experimental conditions and structure refinement parameters of the compound (Ia) and (Ib). 
  
alcohol (15 mL) and heated to reflux for 60 min. After 
completion of the reaction as evident from TLC, the 
mixture was poured into water (50 mL), the precipi-
tated solid was filtered and washed with water (100 
mL) to obtain pure yellow solid having a melting point 
of 226°C  (Yield : 95%)  
 
Structure Determination and Refinement 
Single crystal X-ray intensity data of compound (Ia) 
and compound (Ib) were collected using Bruker 
SMART APEX2 CCD diffractometer with MoKα ra-
diation (λ=0.71073Å) at room temperature (293 K). 
The data reduction was performed with SAINT 
(Bruker, 2004). An absorption correction was made 
using the ω-scan method. The structures of both com-
pounds were solved using the direct methods 
SHELXS97 (Sheldrick 2008) and all the non-hydrogen 
atoms were refined anisotropically by full matrix least-
squares based on the F2 of all unique reflections using 
SHELXL97 (Sheldrick 2008). Molecular graphics 
were drawn using PLATON (Spek 2009). The hydro-
gen atoms were placed in calculated positions and in-
cluded in the refinement using the riding model with 
C—H = 0.93–0.98 Å and Uiso = 1.2Ueq(C,) for the 
CH, CH2 groups and Uiso = 1.5Ueq(C) for the CH3 
group. The crystal data, experimental conditions and 
structure refinement parameters for the compounds 
(Ia) and (Ib) are presented in Table 1. 
Results and Discussion 
 
Spectral Data 
The structure of the compounds (Ia) and (Ib) has been 
elucidated using 1H, 13C and two dimensional NMR 
spectroscopic studies. The 1H and 13C NMR chemical 
shifts of (Ia) and (Ib) are shown in Figure 2. 
 It is interesting to observe that the chemical 
shifts of 2′-CH2 of (Ia) (2.96 ppm and ~1.70 ppm) and 
(Ib) (3.20 ppm ~1.27 ppm) differ greatly by 1.26 and 
1.93 ppm, respectively. This suggests that probably the 
H-2eq is spatially proximate to the carbonyl of ace-
naphthylen-1(2H)-one, shifting it downfield, while H-
2ax lies in the shielding zone of the acenaphthylen-1
(2H)-one ring, shifting it downfield, suggesting rela-
tive configuration at C-2 for (Ia) and (Ib). The alterna-
tive stereochemistry with inversion of the configura-
tion at C-2 relative to that shown on (Ia) or (Ib), bring-
ing both the carbonyls of the piperidone and acenap-
thene rings towards each other in spatial proximity, 
probably renders the transition state of the cycloaddi-
tion unstable by electrostatic repulsion, which could 
raise the free energy of activation (transition state B in 
Figure 3) relative to the transition state leading to the 
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Figure 3. Stereochemistry of formation of cycloadducts  
differing in their configurations at C-2. 
Figure 4. The molecular structure of compound (Ia) (left) and (Ib) (right) showing the atom numbering scheme. Displacement 
ellipsoids are drawn at 30% probability level, using ORTEP 3. Hydrogen atoms are drawn as spheres of arbitrary size. 
formation of (Ia) or (Ib) with both carbonyls placed 
far off (transition state A in Figure 3). 
 The biological activity studies of the com-
pounds (Ia) and (Ib) are presently in progress. Apart 
from screening these compounds against MTB, their 
activity against Alzheimer’s disease and cancer is also 
being examined. 
 
Crystal structure 
Figure 4 shows the ORTEP plot, drawn at 30 % prob-
ability displacement ellipsoids of compound (Ia) and 
(Ib) and the atom-numbering scheme. The six mem-
bered piperidine rings in the title compounds adopt 
twisted half chair conformation as evident from puck-
ering parameters Q = 0.567(3) Å, θ = 134.8(3)° and Φ 
= 140.3(5)° in compound (Ia) and Q = 0.554(3) Å, θ = 
33.1(3)° and   Φ = 316.6(5)° in compound (Ib) 
(Cremer & Pople 1975). The differences in the devia-
tions are due to steric hinderance of the different sub-
stituents at the C3 and C5 positions of the piperidine 
ring. The olefinic double bond in the structures has an 
E configuration. From the puckering parameters, Q = 
0.393(3) Å and Φ = 10.3(5)° in compound (Ia) as well 
as Q = 0.439(3) Å and Φ = 207.7(4) in compound (Ib) 
(Cremer & Pople 1975), the pyrrole ring is shown to 
be in a twisted envelope conformation. 
 The piperidine of octahydroindolizine ring is 
in half chair conformation as their puckering parame-
ters are Q = 0.573(4) Å, θ = 177.9(4)° and Φ = 220(9)° 
in compound (Ia) and Q = 0.568(3) Å, θ = 0.0(3)° and 
Φ = 127(14)° in compound (Ib) (Cremer & Pople 
1975).  The dihedral angles between the piperidone 
mean plane and the aryl rings are 45.29(1)° , 84.01(1)° 
in (Ia) and 66.23 (1)°, 87.03 (1)° in (Ib), respectively. 
As a result, the torsion angle C3-C31-C32-C33 has the 
value 41.50(3)° in (Ia) and -51.55(3)° in (Ib). This 
lack of coplanarity is caused by nonbonded interac-
tions between one of the ortho H atoms in the aryl ring 
and the equatorial H atoms at the 2-position of the 
piperidone ring (H33/H2A or H2B). As a result of 
these steric repulsions the bond angle C3-C31-C32 is 
expanded in both compounds, being 128.75 (19)° in 
(Ia) and 127.48(18)° in (Ib), instead of 120°. The bro-
mophenyl rings are planar, as confirmed by the values 
of the r.m.s. deviation; 0.0038 and 0.0163Å in com-
pound (Ia), 0.0118 and 0.0122 in compound (Ib). The 
dihedral angle between the bromophenyl rings is 72.2
(1)° and 63.09(1)° in (Ia) and (Ib), respectively. These 
rings are making angles of 35.4 (1)° and 74.3 (1)° in 
(Ia), 41.89(1)° and 79.92(1)° in (Ib), with their respec-
tive acenaphthene group. 
 The Csp
2 to Csp
2 distances in the acenaphthene 
group  ranges from    1.335 (3) (C19-C20) to 1.570 (2) 
Å (C13-C14) in (Ia), 1.400 (3) (C19-C20) to 1.572(2) 
Å (C13-C14) in (Ib) and the C-C-C bond angles 
ranges from 101.02 (16)° in (Ia), 101.94(16)° in (Ib)  
(C14-C13-C17) to 123.58 (2)° in (Ia) and 122.71(2)° 
in (Ib) (C15-C16-C21). These values are in agreement 
with previously reported values of related structures 
(Hazell et al, 1976; Hazell et al, 1977; Jones et al, 
1992; Sundar et al, 2002). The C8-N2 bond distance, 
being 1.454Å (3) ° in (Ia) and 1.461Å (3) ° in (Ib) is 
comparable to the Csp
2-Nsp
2 distances found in similar 
structures (Sussman et al. 1973, Wodak et al. 1975). In 
both crystal structures weak C—H···O interactions 
have been observed (see Table 2 and 3). 
 
Crystal Packing  
In the crystal structure of the compound (Ia) the adja-
cent molecules are connected via a C34—H34···O2 
interaction, leading to a chain C1
1(11) motif (Bernstein 
et al, 1995) around the inversion centers of the unit 
cell. These motifs form a linear infinite chain running 
along the a-axis, as shown in Figure 5. In the crystal 
structure of the compound (Ib) the adjacent molecules 
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Figure 5. Linear zigzag chain motif C1
1(11) of compound 
(Ia). 
Figure 6. Linear chain motif C1
1(7) of compound (Ib). 
are connected via a C1—H1C···O1 interaction, leading 
to a chain C1
1(7) motif (Bernstein et al. 1995) around 
the inversion centers of the unit cell. These motifs 
form a linear infinite chain running along the b-axis as 
shown in Figure 6. Neither C-H…O nor C-H…π inter-
actions are observed between these chains. However 
there are several van der Walls interactions between 
them in both compounds. Inter molecular and intra 
molecular hydrogen bond geometry of molecules (Ia) 
and (Ib) are listed in Tables 2 and 3, respectively. 
*The symmetry transformations used to generate equivalent 
atoms are the following: 
(i) 1- x, ½+y, ½- z 
*The symmetry transformations used to generate equivalent 
atoms are the following: 
(i) -1+x,y,z 
 
Conclusion  
 
Spiro[2.2"]acenaphthene-1"-onespiro[3.3']-5'-(2-
bromophenylmethylidene)-1'-methylpiperidin-4'-one-4
-(2-bromophenyl)octahydroindolizine (Ia) and spiro
[2 .2" ]acenaphthene -1" -onespi ro[3 .3 ' ] -5 ' - (4 -
bromophenylmethylidene)-1'-methylpiperidin-4'-one-4
-(4-bromophenyl) octahydroindolizine (Ib) were syn-
thesized. The single crystals of compounds (Ia) and 
(Ib) were obtained by the slow evaporation method 
(solvent: 1:1 ethyl acetate-ethanol). The conforma-
tional features of the compounds (Ia) and (Ib) in the 
solid and liquid phase are discussed, using X-ray and 
NMR methods, respectively. The bond angles C3-C31-
C32 and C8-C7-C71 presented here and the values 
found in similar structures (Suresh et al. 2012) are use-
ful in the design of additional analogues. The replace-
ment of the equatorial H atoms at the 2- and 6-
positions, and the inclusion of substituents of varying 
sizes at atoms C33, C37, C72 and C76, are likely to 
alter the C3-C31-C32 and C8-C7-C71 bond angles.  
Correlations have been established between the bond 
angle values and bioactivity (Pandeya & Dimmock 
1977).  In addition, the increased ψ values would lead 
to variations in the relative locations of the aryl rings, 
which could affect the alignment of these rings at a 
binding site and hence influence bioactivity (Quail et 
al. 2005). Further studies on structure-bio activity rela-
tionships of these compounds are in progress in our 
research group. 
 
Supplementary Material 
 
Crystallogtaphic data (excluding structure fac-
tors) for the structures of (Ia) and (Ib) reported in this 
paper have been deposited with the Cambridge Crys-
tallographic data Centre as supplementary publication 
CCDC 892957 & CCDC 892958. Copies of the data 
can be obtained, free of charge, on application to, 
CCDC, 12 Union Road, Cambridge, and CB2 1 EZ 
UK; Fax: 044-1223-336033; Email: de-
posit@ccdc.cam.uk or at: http://www.ccdc.cam.ac.uk/. 
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